Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Norma E Farrow"'
Autor:
Elliott R. Haut, Oluwafemi P. Owodunni, Jiangxia Wang, Dauryne L. Shaffer, Deborah B. Hobson, Gayane Yenokyan, Peggy S. Kraus, Norma E. Farrow, Joseph K. Canner, Katherine L. Florecki, Kristen L.W. Webster, Christine G. Holzmueller, Jonathan K. Aboagye, Victor O. Popoola, Mujan Varasteh Kia, Peter J. Pronovost, Michael B. Streiff, Brandyn D. Lau
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 18 (2022)
Background Many hospitalized patients are not administered prescribed doses of pharmacologic venous thromboembolism prophylaxis. Methods and Results In this cluster‐randomized controlled trial, all adult non–intensive care units (10 medical, 6 su
Externí odkaz:
https://doaj.org/article/cf123f883da349169b6c0d5b54826a7b
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, David Boczkowski, Michael C Brown, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Rami N Al-Rohil, Aaron D Therien, Junheng Gao, Eda K Holl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients al
Externí odkaz:
https://doaj.org/article/04605eb95ab14089a2829c1d83ca4646
Autor:
Aaron D. Therien, Georgia M. Beasley, Kristen E. Rhodin, Norma E. Farrow, Douglas S. Tyler, David Boczkowski, Rami N. Al-Rohil, Eda K. Holl, Smita K. Nair
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionB cells are key regulators of immune responses in melanoma. We aimed to explore differences in the histologic location and activation status of B cell follicles in sentinel lymph nodes (SLN) of melanoma patients.MethodsFlow cytometry was
Externí odkaz:
https://doaj.org/article/b9f0f4ada7424c5ebc1dcb3d7d1046ae
Autor:
Yun Song, John F Thompson, Frances A Collichio, Tasha Hughes, John Vetto, Dale Han, Jonathan Zager, Zeynep Eroglu, Jennifer Downs, David E Gyorki, Nikhil I Khushalani, Alexander van Akkooi, Georgia Beasley, Lisa Kottschade, Hidde M Kroon, Ann Lee, Norma E Farrow, Giorgos Karakousis, Michael Lowe, Avinash Sharma, Kristy K Broman, Amanda Nijhuis, Tina J Hieken, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Lesly Dossett, Russell S Berman, Emma Stahlie, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, David W Ollila, Roger Olofsson Bagge, Jan Mattsson, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial
Externí odkaz:
https://doaj.org/article/5e2609c2e5e44274aabf900f1ff2c1c7
Publikováno v:
Oncology and Therapy, Vol 8, Iss 2, Pp 261-275 (2020)
Abstract Introduction Since 2011, encouraging clinical trial results have led to approval of multiple new therapies for advanced melanoma, but the impact of these therapies outside of trial populations is largely unknown. This study examines use of n
Externí odkaz:
https://doaj.org/article/0bd8cac7d82049b5a9bfcef95fc39e34
Autor:
Avani M. Kolla BPhil, Gerardo A. Vitiello MD, Erica B. Friedman MD, James Sun MD, Aishwarya Potdar MS, Hala Daou BS, Norma E. Farrow MD, Clara R. Farley MD, John T. Vetto MD, Dale Han MD, Marvi Tariq MD, Georgia M Beasley MD, Carlo M. Contreras MD, Michael Lowe MD, Jonathan S. Zager MD, Iman Osman MD, Russell S. Berman MD, Tracey N. Liebman MD, Jennifer A. Stein MD PhD, Ann Y. Lee MD
Publikováno v:
Cancer Control, Vol 28 (2021)
Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic f
Externí odkaz:
https://doaj.org/article/57f410acb38d4768a497f22089e561a6
Autor:
Kristy K, Broman, Tasha M, Hughes, Brooke C, Bredbeck, James, Sun, Dennis, Kirichenko, Michael J, Carr, Avinash, Sharma, Edmund K, Bartlett, Amanda A G, Nijhuis, John F, Thompson, Tina J, Hieken, Lisa, Kottschade, Jennifer, Downs, David E, Gyorki, Emma, Stahlie, Alexander, van Akkooi, David W, Ollila, Kristin, O'shea, Yun, Song, Giorgos, Karakousis, Marc, Moncrieff, Jenny, Nobes, John, Vetto, Dale, Han, Meghan, Hotz, Jeffrey M, Farma, Jeremiah L, Deneve, Martin D, Fleming, Matthew, Perez, Kirsten, Baecher, Michael, Lowe, Roger Olofsson, Bagge, Jan, Mattsson, Ann Y, Lee, Russell S, Berman, Harvey, Chai, Hidde M, Kroon, Juri, Teras, Roland M, Teras, Norma E, Farrow, Georgia M, Beasley, Jane Yuet Ching, Hui, Lukas, Been, Schelto, Kruijff, Brandy, Sinco, Amod A, Sarnaik, Vernon K, Sondak, Jonathan S, Zager, Lesly A, Dossett
Publikováno v:
Annals of Surgery. 277(5):1106-1115
Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Da
Autor:
Marcelo Cerullo, Hui-Jie Lee, Christopher Kelsey, Norma E. Farrow, Charles D. Scales, Betty C. Tong
Publikováno v:
The Annals of Thoracic Surgery. 115:338-345
Stereotactic body radiation therapy (SBRT) is used to treat stage I non-small cell lung cancer (NSCLC) in nonsurgical candidates, although guidelines specify that inoperability be determined in multidisciplinary fashion. We characterized NSCLC patien
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Carol Ann Wiggs, Andrea True Kelly, April KS Salama
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chime
Externí odkaz:
https://doaj.org/article/e28cb6ceb21645b987a84e695f9c4187
Publikováno v:
Annals of Surgical Oncology. 30:2586-2589